Pipeline

By leveraging our deep expertise in protein drug discovery, our immunotherapy pipeline has been specifically curated to target clinically validated as well as emerging mechanisms, positioning our portfolio to pursue both best-in-class and first-in-class approaches.

ProgramMechanism of ActionLead IDLead OPIND EnablingClinic
BPT567
(PD1-IL18)
Immuno-oncology
 PD-1 blockade
+ tumor targeting
+ IL-18 signaling
IL-18 binding protein resistant

 

IL-18 is a strong stimulator of both innate and adaptive immunity, which makes it a potent and attractive therapeutic candidate for cancer immunotherapy. Native IL-18 cytokine activates the IL-18 receptor to induce proinflammatory effects including potent induction of IFNγ, but also binds to a negative feedback inhibitor, IL-18 Binding Protein (IL-18BP). IL-18BP is frequently upregulated and abundant in the tumor microenvironment and is also induced by IFNγ in a natural negative feedback loop. In patients, IL-18BP binds native IL-18 and blocks the cytokine from activating its receptor, leading to a ‘quenching’ effect and ultimately tachyphylaxis.

Bright Peak’s enhanced IL-18 cytokine payload is specifically engineered to preferentially activate the IL-18 receptor without binding to IL-18BP – triggering potent pro-inflammatory signaling in antitumor immune cells without being neutralized by IL-18BP.

PD1-IL18 consists of Bright Peak’s enhanced IL-18 payload chemically conjugated to LZM009, an anti-PD-1 antibody now in late-stage clinical development. PD1-IL18 targets PD-1+ (antigen-experienced) T cells in the tumor and simultaneously blocks PD-1 while stimulating the IL-18 receptor on the surface of same PD-1+ T cell (cis-signaling) to generate synergistic anti-tumor efficacy.

close x
BPT331
(PD1-IL2)
Immuno-oncology
 PD-1 blockade
+ tumor targeting
+ β/γ-selective IL-2 signaling
α-dead β-enhanced

 

PD1-IL2 consists of Bright Peak’s enhanced IL-2 payload chemically conjugated to LZM009, an anti-PD-1 antibody now in late-stage clinical development. IL-2 is a master immune-stimulating cytokine with proven efficacy in patients with cancer. PD1-IL2 is designed to target and block PD-1 and simultaneously bind the IL-2 receptor on the surface of the same PD-1+ antigen-experienced T cell (cis-signaling) to generate synergistic anti-tumor efficacy.
close x
BPT331CAPS
(PD1-IL2CAPS)
Immuno-oncology
 PD-1 blockade
+ tumor-selective activation
+ β/ γ-selective IL-2 signaling
α-dead β-enhanced
Conditionally activated in the TME

 

PD1-IL2CAPS consists of Bright Peak’s enhanced IL-2 payload chemically conjugated to LZM009, an anti-PD-1 antibody now in late-stage clinical development, with an additional moiety that enables the IL-2 payload to be conditionally activated when encountering the tumor microenvironment (conditionally activated protein structure or "CAPS") for a potentially expanded therapeutic window and greater safety margin.
close x
 
Numerous undisclosed discovery assets in IO & Autoimmune disease

 

This space intentionally left blank
close x
DrugPhase
BPT567
(PD1-IL18)
Immuno-oncology
IND Enabling
BPT331
(PD1-IL2)
Immuno-oncology
IND Enabling
BPT331CAPS
(PD1-IL2CAPS)
Immuno-oncology
Lead OP
 
Numerous undisclosed discovery assets in IO & Autoimmune disease
Lead OP

BPT567
(PD1-IL18)

IL-18 is a strong stimulator of both innate and adaptive immunity, which makes it a potent and attractive therapeutic candidate for cancer immunotherapy. Native IL-18 cytokine activates the IL-18 receptor to induce proinflammatory effects including potent induction of IFNγ, but also binds to a negative feedback inhibitor, IL-18 Binding Protein (IL-18BP). IL-18BP is frequently upregulated and abundant in the tumor microenvironment and is also induced by IFNγ in a natural negative feedback loop. In patients, IL-18BP binds native IL-18 and blocks the cytokine from activating its receptor, leading to a ‘quenching’ effect and ultimately tachyphylaxis.

Bright Peak’s enhanced IL-18 cytokine payload is specifically engineered to preferentially activate the IL-18 receptor without binding to IL-18BP – triggering potent pro-inflammatory signaling in antitumor immune cells without being neutralized by IL-18BP.

PD1-IL18 consists of Bright Peak’s enhanced IL-18 payload chemically conjugated to LZM009, an anti-PD-1 antibody now in late-stage clinical development. PD1-IL18 targets PD-1+ (antigen-experienced) T cells in the tumor and simultaneously blocks PD-1 while stimulating the IL-18 receptor on the surface of same PD-1+ T cell (cis-signaling) to generate synergistic anti-tumor efficacy.

BPT331
(PD1-IL2)

PD1-IL2 consists of Bright Peak’s enhanced IL-2 payload chemically conjugated to LZM009, an anti-PD-1 antibody now in late-stage clinical development. IL-2 is a master immune-stimulating cytokine with proven efficacy in patients with cancer. PD1-IL2 is designed to target and block PD-1 and simultaneously bind the IL-2 receptor on the surface of the same PD-1+ antigen-experienced T cell (cis-signaling) to generate synergistic anti-tumor efficacy.

BPT331CAPS
(PD1-IL2CAPS)

PD1-IL2CAPS consists of Bright Peak’s enhanced IL-2 payload chemically conjugated to LZM009, an anti-PD-1 antibody now in late-stage clinical development, with an additional moiety that enables the IL-2 payload to be conditionally activated when encountering the tumor microenvironment (conditionally activated protein structure or "CAPS") for a potentially expanded therapeutic window and greater safety margin.

 

This space intentionally left blank

MENU '